Öner Tulum, William Lazonic

Innovation Versus Financialization in the Us Pharmaceutical Industry

Sprache: Englisch.
gebunden , 75 Seiten
ISBN 100970799X
EAN 9781009707992
Veröffentlicht 31. Oktober 2025
Verlag/Hersteller Cambridge University Press

Auch erhältlich als:

Taschenbuch
22,00
71,00 inkl. MwSt.
vorbestellbar (Versand mit Deutscher Post/DHL)
Teilen
Beschreibung

Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.

Das könnte Sie auch interessieren

vorbestellbar
16,99
Phia Quantius
Aura
Taschenbuch
vorbestellbar
20,00
"König Boris" Lauterbach
FC St. Pauli
Gebund. Ausgabe
vorbestellbar
16,99
Walter Moers
Qwert
Gebund. Ausgabe
vorbestellbar
42,00
Senlinyu
Alchemised
Gebund. Ausgabe
vorbestellbar
34,99
vorbestellbar
3,50
vorbestellbar
5,95
Jeff Kinney
Gregs Tagebuch 20 - Bock auf Party?
Gebund. Ausgabe
vorbestellbar
16,00
Misty Wilson
Falling Like Leaves
Taschenbuch
vorbestellbar
17,00
Thomas Melle
Haus zur Sonne
Gebund. Ausgabe
vorbestellbar
24,00